Selection of fitness-associated substitutions in patients failing NS5A inhibitors based therapy : analysis of HCV full-length genome deep sequencing by means of shotgun metagenomics- Slim Fourati

European Meeting on HIV & Hepatitis 2018

Evaluation of pre-treatment risk factors associated with failure in HCVinfected patients naive to direct acting antivirals: particular focus on natural resistance- Silvia Barbaliscia

European Meeting on HIV & Hepatitis 2018

Acute hepatitis A to E, diagnosis and management - Thomas Berg, MD

European Meeting on HIV & Hepatitis 2018

B/F/TAF in treatment-naïve HIV-1 and HIV-1 RNA suppressed switch patients- Kirsten White, MD, PhD

European Meeting on HIV & Hepatitis 2018

Clinical development of ABX464, drug candidate for HIV functional cure- Jean-Marc Steens, MD

European Meeting on HIV & Hepatitis 2018

Reduced drug regimens- Andrea De Luca, MD

European Meeting on HIV & Hepatitis 2018

What is the place of the monoclonal antibodies in the clinic- Julià Blanco, PhD

European Meeting on HIV & Hepatitis 2018

Hepatitis E in HIV- Kenneth Sherman, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

News on hepatitis delta and HIV infections- Vincent Soriano, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Management of HCV in intravenous drug users: special considerations- Rui Sarmento e Castro, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

EASL highlights 2017- Jürgen Rockstroh, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Management of end-stage liver disease in HIV patients- Ana Morbey, MD

International Workshop on HIV & Hepatitis Co-infection 2017

New insights in management of HIV/HBV co-infected patients- Juan Berenguer, MD

International Workshop on HIV & Hepatitis Co-infection 2017

HBV cure: what is coming in 5 – 10 years?- Patrick Kennedy, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Debate case based: Do we need resistance testing in HCV therapy to guide decision making? Pro stance- Francesca Ceccherini– Silberstein, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Special considerations before / during / after DAA therapy- Kosh Agarwal, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Virologist's perspective - Charles Boucher, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Debate case based: Do we need resistance testing in HCV therapy to guide decision making? Con stance (Not available)- Mark Nelson, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Pharmacologist's perspective- David Back, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Are there any special populations in treatment of HCV left?- Douglas Dieterich, MD

International Workshop on HIV & Hepatitis Co-infection 2017

HCV chronic infection treatment with DAA: who are the patients that are not achieving sustained virologic response?- R. Valente

International Workshop on HIV & Hepatitis Co-infection 2017

HCV genotype 3 DAA treatment in a cohort of 284 HIV co-infected patients: a multicenter, observational, retrospective portuguese study- D. Seixas

International Workshop on HIV & Hepatitis Co-infection 2017

Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1- P. Buggish

International Workshop on HIV & Hepatitis Co-infection 2017

Clinical evolution of porphyria cutanea tarda (PCT) in HCV monoinfected and HIV/HCV co-infected patients after viral eradication with direct acting agents (DAA)- P. Rodriguez Cortes

International Workshop on HIV & Hepatitis Co-infection 2017